Naomi Burns1. 1. Brighton General Hospital, Elm Grove, Brighton BN2 3EW, UK. naomi.burns@bsuh.nhs.uk
Abstract
OBJECTIVE: To compare the effectiveness of pharmacists dosing warfarin for in-patients, in comparison to that of junior doctors, in order to establish the value of a pharmacist-controlled in-patient anti-coagulation service. SETTING: Brighton and Sussex University Hospitals NHS Trust (BSUH). METHOD: Two wards at Brighton General Hospital were under pharmacist-control of warfarin dosing and three wards remained under the care of doctors. Data was collected for 11 months and a total of 33 patients were recruited into each arm. RESULTS: Pharmacists prescribed more appropriate loading and maintenance doses (according to the Trust's Prescribing Guidelines) compared to doctors. This resulted in more patients reaching their target INR sooner. Documentation of indication, duration of treatment and target INR was also much improved compared to medical staff. However, more patients (73%) in the doctors' group were within range on discharge and at the out-patient clinic (79%), compared to the pharmacists (68% & 61% respectively). This could not be explained entirely. Significantly fewer patients dosed by pharmacists had episodes of over or under anti-coagulation (91% vs 67%) and fewer INR tests were requested (2.3/patient/week) compared to those dosed by doctors (2.7). Patients under the control of pharmacists also had fewer adverse events (6% vs 12%). One major GI bleed occurred in the doctors' group. CONCLUSION: Pharmacist dosing of warfarin for in-patients had a beneficial effect on most aspects of anti- coagulation control. This study therefore provides further evidence to support the extended role pharmacists can play with the benefit of reducing risk, junior doctors' hours and improving patient care.
OBJECTIVE: To compare the effectiveness of pharmacists dosing warfarin for in-patients, in comparison to that of junior doctors, in order to establish the value of a pharmacist-controlled in-patient anti-coagulation service. SETTING: Brighton and Sussex University Hospitals NHS Trust (BSUH). METHOD: Two wards at Brighton General Hospital were under pharmacist-control of warfarin dosing and three wards remained under the care of doctors. Data was collected for 11 months and a total of 33 patients were recruited into each arm. RESULTS: Pharmacists prescribed more appropriate loading and maintenance doses (according to the Trust's Prescribing Guidelines) compared to doctors. This resulted in more patients reaching their target INR sooner. Documentation of indication, duration of treatment and target INR was also much improved compared to medical staff. However, more patients (73%) in the doctors' group were within range on discharge and at the out-patient clinic (79%), compared to the pharmacists (68% & 61% respectively). This could not be explained entirely. Significantly fewer patients dosed by pharmacists had episodes of over or under anti-coagulation (91% vs 67%) and fewer INR tests were requested (2.3/patient/week) compared to those dosed by doctors (2.7). Patients under the control of pharmacists also had fewer adverse events (6% vs 12%). One major GI bleed occurred in the doctors' group. CONCLUSION: Pharmacist dosing of warfarin for in-patients had a beneficial effect on most aspects of anti- coagulation control. This study therefore provides further evidence to support the extended role pharmacists can play with the benefit of reducing risk, junior doctors' hours and improving patient care.
Authors: W E Dager; J M Branch; J H King; R H White; R S Quan; N A Musallam; T E Albertson Journal: Ann Pharmacother Date: 2000-05 Impact factor: 3.154
Authors: Peter C Wierenga; Joanna E Klopotowska; Susanne M Smorenburg; Hendrikus J van Kan; Yuma A Bijleveld; Marcel G Dijkgraaf; Sophia E de Rooij Journal: Drugs Aging Date: 2011-04-01 Impact factor: 3.923
Authors: Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Joanna E Klopotowska; Peter C Wierenga; Sophia E de Rooij; Clementine C Stuijt; Lambertus Arisz; Paul F Kuks; Marcel G Dijkgraaf; Loraine Lie-A-Huen; Susanne M Smorenburg Journal: BMC Health Serv Res Date: 2011-05-25 Impact factor: 2.655